Biosimilars in rheumatology: out of the laboratory and into practice

Expert Rev Clin Immunol. 2016 Jul;12(7):697-9. doi: 10.1080/1744666X.2016.1191946. Epub 2016 Jun 1.

Authors

Andrew I Rutherford¹, James B Galloway²

Affiliations

¹ a Academic Department of Rheumatology, NIHR Biomedical Research Centre at Guy's and St Thomas' NHS Foundation Trust and King's College London , London , UK.
² b Academic Department of Rheumatology , King's College London , London , UK.

PMID: 27195989
DOI: 10.1080/1744666X.2016.1191946

No abstract available

Keywords: Biologic; anti-TNF; biosimilar; drug therapies; rheumatoid arthritis.

Publication types

Editorial
Research Support, Non-U.S. Gov't

MeSH terms

Arthritis, Rheumatoid / drug therapy*
Biosimilar Pharmaceuticals / therapeutic use*
Biotechnology
Etanercept / therapeutic use
Humans
Infliximab / therapeutic use
Patents as Topic
Rheumatology*
Translational Research, Biomedical
United Kingdom

Substances

Biosimilar Pharmaceuticals
Infliximab
Etanercept